IFRX compared with VTGN: revenue, margins and what each company keeps, and the suppliers and customers both name

IFRXInflaRx N.V.

Mkt capRevenueRevenue

VTGNVistagen Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

IFRXInflaRx N.V.

VTGNVistagen Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

IFRX

No earnings history for IFRX.

VTGN1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q1 FY27±80.3%▲+0.49%×0.01

= impliedIFRX realized, solidVTGN realized, hatchedOne scale, both sides: full bar = 81%× = |realized| ÷ impliedSource: market data

IFRXInflaRx N.V.

1.31▼−3.32%· post 1.31

Mkt cap$94.3MRevenue—Revenue—

VTGNVistagen Therapeutics, Inc.

0.17▲+2.06%· post 0.17

ClosedNov 6 '26

Mkt cap$7.3MRevenue$1MQ1 FY27Revenue$1MFY26

Compare

ClosedNov 6 '26

IFRXInflaRx N.V.

VTGNVistagen Therapeutics, Inc.

1.31▼−3.32%post 1.31

Price

0.17▲+2.06%post 0.17

$94.3M

Mkt cap

$7.3M

—

Revenue

$1MQ1 FY27

—

Revenue

$1MFY26

IFRX1.31▼−3.32%vsVTGN0.17▲+2.06%ClosedNov 6 '26